Uncategorised - European Medical Journal

Coins on blue background

AstraZeneca bets big on China with $15bn investment

Pascal Soriot, CEO, AZ, hailed the investment as the start of “an exciting next chapter” for the company in China.

CT Biomarkers and Survival in Oesophageal Cancer - EMJ

CT Biomarkers Linked to Oesophageal Cancer Survival

Sarcopenia, myosteatosis, and systemic immune inflammatory index were independently associated with reduced oesophageal cancer survival in patients treated with immunotherapy, supporting their role in prognostic assessment.

Inflammatory Arthritis Can Emerge Years After Bariatric Surgery

A case series published in BMC Rheumatology describes new-onset inflammatory arthritis following bariatric surgery, with MRI-confirmed axial and peripheral disease requiring advanced treatment.

Does Bisoprolol Benefit Patients with COPD? - EMJ

Does Bisoprolol Benefit Patients with COPD?

A major trial finds the beta blocker bisoprolol neither improves nor worsens outcomes in people with COPD, despite their high cardiovascular risk.

EAHD web

Hema Now: Behind the Scenes of EAHAD 2026

In this latest episode of Hema Now, we go behind the scenes of the EAHAD 2026 Congress, exploring how the programme is developed, key emerging priorities, and what lies ahead for haemophilia care in Europe.

Global hepatitis elimination profiles reveal policy gaps - EMJ

Global Report Highlights Policy Gaps in Hepatitis Elimination Efforts

A global report shows uneven progress toward WHO hepatitis elimination goals, highlighting persistent policy and implementation gaps in testing and treatment.

Patient integration concept in oncology research planning meeting with patient advocate and clinical researchers

Patient Integration in Oncology Research Gains Urgency

Patient integration in oncology research can align therapies with needs by translating science into outcomes patients value, today.

Mobile app engagement and pain outcomes in adults with chronic pain and hazardous drinking

Mobile App Predicts Pain Relief in Hazardous Drinking

Mobile application engagement may predict clinically meaningful pain reduction for adults with chronic pain and hazardous drinking.

Bimekizumab▼in hidradenitis suppurativa (HS)

Experts explore 3-year clinical data on bimekizumab presented at the 2025 EADV and SHSA congresses, highlighting its durable and deep…

30 Jan 2026

Putting the Pieces Together: A Patient-Centred Approach to Bronchiectasis Diagnosis

Putting the Pieces Together: A Patient-Centred Approach to Bronchiectasis Diagnosis…